Major histocompatibility complex class II–T cell receptor interface

The **major histocompatibility complex class II–T cell receptor (MHC class II–TCR) interface** is not a single molecule, but instead refers to the molecular contact surface formed between an MHC class II molecule (commonly found on antigen-presenting cells) and the antigen-specific T cell receptor present on CD4⁺ helper T cells. MHC class II molecules present processed antigenic peptides on the surface of antigen-presenting cells, where they are recognized by T cell receptors. This interaction is crucial for initiating the adaptive immune response, enabling T cells to distinguish self from non-self and mount immune responses against pathogens or abnormal self cells[1][2][4][6][7]. The interface is a structural and functional assembly zone, not a singular druggable protein, and is defined by highly variable contacts that depend on the MHC allele, the peptide bound, and the TCR clone involved[7]. From a therapeutic perspective, the interface itself is not conventionally referred to as a molecular "target" (as in, for drugging a receptor or enzyme), although both MHC class II molecules and T cell receptors are themselves considered therapeutic targets, especially in the context of immunomodulatory drugs, cancer immunotherapy, and treatments for autoimmune diseases[2][3][4][6]. **Note:** - This "target" represents an inter-molecular interface rather than a discrete single molecule, so it is not formally considered a drug target in medicinal chemistry or pharmacology nomenclature. - Drugs and therapeutic agents may target individual components (e.g., blocking MHC class II, modulating TCR signaling), but there are no drugs that directly and specifically target the "MHC class II–T cell receptor interface" as a singular entity[4][6][7][3]. - The interface is critical from a mechanistic and structural biology standpoint for understanding immune recognition and T cell activation[6][1][7].

Other names

MHC class II–TCR interfaceMHC II–TCR interface